BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26933997)

  • 41. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.
    Geng J; Li X; Lang X; Qiao C; Hu M; Yang J; Feng J; Lv M
    Technol Cancer Res Treat; 2014 Aug; 13(4):377-85. PubMed ID: 24325131
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA.
    Lang Q; Ling C
    Biochem Biophys Res Commun; 2012 Sep; 426(2):247-52. PubMed ID: 22940133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.
    Lu PH; Chen MB; Liu YY; Wu MH; Li WT; Wei MX; Liu CY; Qin SK
    Oncotarget; 2017 Apr; 8(14):22800-22810. PubMed ID: 28206952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
    Zhao P; Chen L; Li LH; Wei ZF; Tong B; Jia YG; Kong LY; Xia YF; Dai Y
    BMC Cancer; 2014 Dec; 14():987. PubMed ID: 25527123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GDC-0084 inhibits cutaneous squamous cell carcinoma cell growth.
    Ding LT; Zhao P; Yang ML; Lv GZ; Zhao TL
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1941-1948. PubMed ID: 30072096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
    Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
    Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.
    Chen L; Tian H; Li M; Ge C; Zhao F; Zhang L; Li H; Liu J; Wang T; Yao M; Li J
    Tumour Biol; 2016 May; 37(5):5951-61. PubMed ID: 26596832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Telomerase inhibition decreases alpha-fetoprotein expression and secretion by hepatocellular carcinoma cell lines: in vitro and in vivo study.
    Tahtouh R; Azzi AS; Alaaeddine N; Chamat S; Bouharoun-Tayoun H; Wardi L; Raad I; Sarkis R; Antoun NA; Hilal G
    PLoS One; 2015; 10(3):e0119512. PubMed ID: 25822740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway.
    He C; Wu T; Hao Y
    Biochem Biophys Res Commun; 2018 Sep; 503(4):3093-3099. PubMed ID: 30146257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long non-coding RNA 00312 downregulates cyclin B1 and inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo.
    Wu J; Zhou X; Fan Y; Cheng X; Lu B; Chen Z
    Biochem Biophys Res Commun; 2018 Feb; 497(1):173-180. PubMed ID: 29432732
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DJ-1 knockdown inhibits growth and xenograft‑induced tumor generation of human hepatocellular carcinoma cells.
    Liu S; Long G; Wei H; Shi L; Yang Z; Liu D; Hu G; Qiu H
    Oncol Rep; 2015 Jan; 33(1):201-6. PubMed ID: 25384406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma.
    Xiao Z; Li CH; Chan SL; Xu F; Feng L; Wang Y; Jiang JD; Sung JJ; Cheng CH; Chen Y
    Cancer Res; 2014 Nov; 74(21):6236-47. PubMed ID: 25217526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
    Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H
    Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
    Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS
    Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Growth inhibition by pennogenyl saponins from Rhizoma paridis on hepatoma xenografts in nude mice.
    Chen YS; He Y; Chen C; Zeng Y; Xue D; Wen FY; Wang L; Zhang H; Du JR
    Steroids; 2014 May; 83():39-44. PubMed ID: 24530287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.